Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination

Simple item page
dc.contributor.authorJamani, Kareem
dc.contributor.authorMacDonald, Judy
dc.contributor.authorLavoie, Martin
dc.contributor.authorWilliamson, Tyler S.
dc.contributor.authorBrown, Christopher B.
dc.contributor.authorChaudhry, Ahsan
dc.contributor.authorJimenez-Zepeda, Victor H.
dc.contributor.authorDuggan, Peter
dc.contributor.authorTay, Jason
dc.contributor.authorStewart, Douglas
dc.contributor.authorDaly, Andrew
dc.contributor.authorStorek, Jan
dc.date.accessioned2017-02-13T23:04:26Z
dc.date.available2017-02-13T23:04:26Z
dc.date.issued2016
dc.description.abstractVaricella zoster virus (VZV) disease (usually cutaneous zoster) occurs frequently after hematopoietic cell transplantation (HCT), and postherpetic neuralgia (PHN) results in poor quality of life. The optimal prophylaxis of VZV disease/PHN has not been established. At our center, before 2008, VZV prophylaxis consisted of ∼1 year of post-HCT acyclovir/valacyclovir (“old strategy”), whereas post-2008 prophylaxis consisted of 2 years of acyclovir/valacyclovir followed by immunization using varicella vaccine (“new strategy”). We performed a retrospective study comparing the cumulative incidence of VZV disease and PHN among patients who completed the old strategy (n = 153) vs the new strategy (n = 125). Patients who completed the old strategy had a significantly higher cumulative incidence of VZV disease (33% vs 17% at 5 years, P ≤ .01) and PHN (8% vs 0% at 5 years, P = .02). In conclusion, VZV prophylaxis with 2 years of acyclovir/valacyclovir followed by vaccination appears to result in a low incidence of VZV disease and may eliminate PHN.en_US
dc.description.refereedYesen_US
dc.identifier.citationJamani, K., MacDonald, J., Lavoie, M., Williamson, T. S., Brown, C. B., Chaudhry, A., Jimenez-Zepeda, V. H., Duggan, P., Tay, J., Stewart, D., Daly, A., & Storek, J. (2016). Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination. Blood Advances, 1(2), 152-159. Accessed February 12, 2017. https://doi.org/10.1182/bloodadvances.2016000836.en_US
dc.identifier.doihttps://doi.org/10.1182/bloodadvances.2016000836
dc.identifier.urihttp://hdl.handle.net/1880/51813
dc.identifier.urihttps://doi.org/10.11575/PRISM/43814
dc.language.isoenen_US
dc.publisherAmerican Society of Hematologyen_US
dc.publisher.departmentHematologyen_US
dc.publisher.facultyMedicineen_US
dc.publisher.institutionUniversity of Calgary and Alberta Health Servicesen_US
dc.publisher.urlhttp://www.bloodadvances.orgen_US
dc.titleZoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccinationen_US
dc.typejournal article
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
152.full.pdf
Size:
1.15 MB
Format:
Adobe Portable Document Format
Description:
Main article
Download
Thumbnail Image
Name:
ba000836-suppl1.pdf
Size:
141.46 KB
Format:
Adobe Portable Document Format
Description:
Supplementary Table
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.95 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Cumming School of Medicine Research & Publications